Sebastian
Salvador de la Barrera
Universidad de Salamanca
Salamanca, EspañaPublicacións en colaboración con investigadores/as de Universidad de Salamanca (1)
2024
-
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury
Spinal Cord, Vol. 62, Núm. 8, pp. 454-467